mutations and sophisticated kar yotype. It follows a linear evolution within the CLL clone throughout the recurrent acquisition of CDKN2A??? "???????????????????????????????????????????????"Duvelisib was the 2nd PI3K inhibitor approved by the FDA, also depending on a phase III randomized demo.130 The efficacy and security profile with the drug surf